Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 23Lymphoma, Non-Hodgkin 14Leukemia, Lymphocytic, Chronic, B-Cell 14Lymphoma, Mantle-Cell 12Lymphoma 12Lymphoma, Follicular 10Lymphoma, B-Cell, Marginal Zone 8Burkitt Lymphoma 8Lymphoma, B-Cell 6Recurrence 5Neoplasms 4Leukemia, Hairy Cell 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia 3Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoproliferative Disorders 2Leukemia, Biphenotypic, Acute 2Leukemia, B-Cell 2Infections 2Epstein-Barr Virus Infections 2beta-Thalassemia 1Thalassemia 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmablastic Lymphoma 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Macular dystrophy, corneal type 1 1Lymphatic Diseases 1

Interventions

Specimen Handling 1Rituximab 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Classic Follicular Lymphoma × Rituximab × 30 days × Clear all
NCT06337318 2026-05-29

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

National Cancer Institute (NCI)

Phase 3 Recruiting
600 enrolled
Lymphoid

Classic Follicular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡